A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients
NCT ID: NCT06496178
Last Updated: 2026-01-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
500 participants
INTERVENTIONAL
2024-06-25
2029-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It is Currently Phase II.).
NCT06719479
Nivolumab Plus Pemetrexed for Head and Neck Squamous Cell Carcinoma
NCT04107103
Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC
NCT05814666
Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT04815720
Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma
NCT05980000
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MCLA-158
Petosemtamab
MCLA-158
Investigator's Choice
Investigator's Choice
Cetuximab
Investigator's Choice
Methotrexate
Investigator's Choice
Docetaxel
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Petosemtamab
MCLA-158
Investigator's Choice
Cetuximab
Investigator's Choice
Methotrexate
Investigator's Choice
Docetaxel
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥ 18 years at signing of ICF.
* Histologically previously confirmed HNSCC with evidence of metastatic or locally advanced disease not amenable to standard therapy with curative intent.
* HNSCC patients progressed on or after anti-PD-1 therapy and platinum-containing therapy.
* The eligible HNSCC primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx.
* Documentation of p16 status (positive or negative) by local laboratory IHC for patients with primary oropharyngeal cancer.
* A baseline new tumor sample unless the patient has an available tumor sample as an FFPE block with sufficient material.
* Measurable disease as defined by RECIST v1.1 by radiologic methods.
* ECOG PS of 0 or 1
* Life expectancy ≥ 12 weeks, as per investigator
* Adequate organ function (as per protocol)
Exclusion Criteria
* Known leptomeningeal involvement
* Any systemic anticancer therapy within 4 weeks of the first dose of study treatment.
* Major surgery or radiotherapy within 3 weeks of the first dose of study treatment.
* Persistent Grade \>1 clinically significant toxicities related to prior antineoplastic therapies
* History of hypersensitivity reaction to any of the excipients of treatment required for this study.
* Unstable angina; history of congestive heart failure of Class II-IV New York Heart Association (NYHA) criteria, or serious cardiac arrhythmia requiring treatment or history of myocardial infarction within 6 months of study entry
* History of prior malignancies with the exception of excised cervical intraepithelial neoplasia or nonmelanoma skin cancer, or curatively treated cancer deemed at low risk for recurrence with no evidence of disease
* Current dyspnea at rest of any origin, or other diseases requiring continuous oxygen therapy
* Current serious illness or medical conditions including, but not limited to, uncontrolled active infection, clinically significant pulmonary, metabolic or psychiatric disorders
* Patients with known infectious diseases (as per protocol)
* Pregnant or breastfeeding patients
* Patient has a primary tumor site of nasopharynx (any histology).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merus N.V.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site 160
Mobile, Alabama, United States
Site 102
Prescott, Arizona, United States
Site 125
Scottsdale, Arizona, United States
Site 82
Duarte, California, United States
Site 25
La Jolla, California, United States
Site 173
Orange, California, United States
Site 28
Palo Alto, California, United States
Site 127
Sacramento, California, United States
Site 46
San Francisco, California, United States
Site 130
Lone Tree, Colorado, United States
Site 104
Washington D.C., District of Columbia, United States
Site 12
Fort Myers, Florida, United States
Site 123
Jacksonville, Florida, United States
Site 9
Orlando, Florida, United States
Site 138
Temple Terrace, Florida, United States
Site 187
Atlanta, Georgia, United States
Site 152
Chicago, Illinois, United States
Site 68
Chicago, Illinois, United States
Site 31
Indianapolis, Indiana, United States
Site 8
Louisville, Kentucky, United States
Site 40
Baton Rouge, Louisiana, United States
Site 100
New Orleans, Louisiana, United States
Site 153
Columbia, Maryland, United States
Site 77
Boston, Massachusetts, United States
Site 103
Ann Arbor, Michigan, United States
Site 5
Detroit, Michigan, United States
Site 49
Maple Grove, Minnesota, United States
Site 124
Rochester, Minnesota, United States
Site 18
St Louis, Missouri, United States
Site 86
Hackensack, New Jersey, United States
Site 15
Albuquerque, New Mexico, United States
Site 24
New York, New York, United States
Site 98
Chapel Hill, North Carolina, United States
Site 122
Durham, North Carolina, United States
Site 23
Cincinnati, Ohio, United States
Site 87
Cleveland, Ohio, United States
Site 32
Columbus, Ohio, United States
Site 26
Portland, Oregon, United States
Site 151
Bensalem, Pennsylvania, United States
Site 158
Philadelphia, Pennsylvania, United States
Site 159
Philadelphia, Pennsylvania, United States
Site 50
Charleston, South Carolina, United States
Site 60
Chattanooga, Tennessee, United States
Site 54
Memphis, Tennessee, United States
Site 59
Nashville, Tennessee, United States
Site 67
Nashville, Tennessee, United States
Site 55
Denison, Texas, United States
Site 34
El Paso, Texas, United States
Site 51
Houston, Texas, United States
Site 7
Houston, Texas, United States
Site 94
Pearland, Texas, United States
Site 4
Salt Lake City, Utah, United States
Site 10
Blacksburg, Virginia, United States
Site 22
Charlottesville, Virginia, United States
Site 156
Winchester, Virginia, United States
Site 163
Seattle, Washington, United States
Site 6
Spokane, Washington, United States
Site 37
Buenos Aires, , Argentina
Site 80
Buenos Aires, , Argentina
Site 58
Caba, , Argentina
Site 193
CABA, , Argentina
Site 45
Córdoba, , Argentina
Site 110
Rosario, , Argentina
Site 57
Viedma, , Argentina
Site 3
Darlinghurst, , Australia
Site 170
Herston, , Australia
Site 38
Melbourne, , Australia
Site 30
Nedlands, , Australia
Site 11
Saint Leonards, , Australia
Site 73
Sydney, , Australia
Site 129
Brussels, , Belgium
Site 56
Brussels, , Belgium
Site 92
Ghent, , Belgium
Site 72
Leuven, , Belgium
Site 108
Liège, , Belgium
Site 69
Namur, , Belgium
Site 154
Brasília, , Brazil
Site 145
Porto Alegre, , Brazil
Site 150
Porto Alegre, , Brazil
Site 146
Recife, , Brazil
Site 155
Rio de Janeiro, , Brazil
Site 148
Rio de Janeiro, , Brazil
Site 147
São Paulo, , Brazil
Site 144
São Paulo, , Brazil
Site 172
Montreal, , Canada
Site 16
Providencia, , Chile
Site 20
Recoleta, , Chile
Site 27
Santiago, , Chile
Site 21
Santiago, , Chile
Site 188
Nový Jičín, , Czechia
Site 105
Bordeaux, , France
Site 162
Le Mans, , France
Site 149
Lille, , France
Site 118
Lyon, , France
Site 115
Marseille, , France
Site 106
Montpellier, , France
Site 169
Nice, , France
Site 114
Paris, , France
Site 167
Paris, , France
Site 136
Poitiers, , France
Site 141
Rennes, , France
Site 107
Rouen, , France
Site 119
Toulouse, , France
Site 142
Vandœuvre-lès-Nancy, , France
Site 113
Villejuif, , France
Site 101
Aachen, , Germany
Site 121
Berlin, , Germany
Site 165
Essen, , Germany
Site 84
Giessen, , Germany
Site 62
Greifswald, , Germany
Site 79
Hamburg, , Germany
Site 88
Hamburg, , Germany
Site 112
Hanover, , Germany
Site 116
Leipzig, , Germany
Site 175
Mannheim, , Germany
Site 168
München, , Germany
Site 99
Würzburg, , Germany
Site 91
Athens, , Greece
Site 96
Athens, , Greece
Site 120
Heraklion, , Greece
Site 126
Rio, , Greece
Site 83
Thessaloniki, , Greece
Site 19
Haifa, , Israel
Site 1
Jerusalem, , Israel
Site 2
Tel Aviv, , Israel
Site 14
Tel Litwinsky, , Israel
Site 93
Brescia, , Italy
Site 111
Cuneo, , Italy
Site 128
Milan, , Italy
Site 81
Milan, , Italy
Site 89
Napoli, , Italy
Site 85
Rozzano, , Italy
Site 132
Chūōku, , Japan
Site 192
Fukuoka, , Japan
Site 131
Kashiwa, , Japan
Site 135
Miki, , Japan
Site 139
Nagoya, , Japan
Site 186
Natori, , Japan
Site 133
Ōsaka-sayama, , Japan
Site 134
Sendai, , Japan
Site 180
Kaunas, , Lithuania
Site 181
Vilnius, , Lithuania
Site 76
Amsterdam, , Netherlands
Site 61
Nijmegen, , Netherlands
Site 66
Utrecht, , Netherlands
Site 190
Bydgoszcz, , Poland
Site 143
Gdansk, , Poland
Site 97
Gliwice, , Poland
Site 177
Krakow, , Poland
Site 117
Skorzewo, , Poland
Site 179
Warsaw, , Poland
Site 182
Coimbra, , Portugal
Site 183
Lisbon, , Portugal
Site 185
Porto, , Portugal
Site 161
Busan, , South Korea
Site 13
Goyang-si, , South Korea
Site 29
Hwasun, , South Korea
Site 137
Seoul, , South Korea
Site 36
Seoul, , South Korea
Site 47
Seoul, , South Korea
Site 33
Soeul, , South Korea
Site 164
Suwon, , South Korea
Site 78
Barcelona, , Spain
Site 109
Madrid, , Spain
Site 75
Madrid, , Spain
Site 71
Madrid, , Spain
Site 166
Madrid, , Spain
Site 63
Pamplona, , Spain
Site 64
Pamplona, , Spain
Site 74
Valencia, , Spain
Site 184
Bellinzona, , Switzerland
Site 189
Geneva, , Switzerland
Site 178
Sankt Gallen, , Switzerland
Site 41
Changhua, , Taiwan
Site 17
Kaohsiung City, , Taiwan
Site 95
Kaohsiung City, , Taiwan
Site 53
Taichung, , Taiwan
Site 176
Tainan, , Taiwan
Site 39
Taipei, , Taiwan
Site 35
Taipei, , Taiwan
Site 52
Taoyuan, , Taiwan
Site 65
Cambridge, , United Kingdom
Site 174
Cardiff, , United Kingdom
Site 171
Glasgow, , United Kingdom
Site 44
Liverpool, , United Kingdom
Site 157
London, , United Kingdom
Site 140
London, , United Kingdom
Site 90
London, , United Kingdom
Site 42
London, , United Kingdom
Site 48
Manchester, , United Kingdom
Site 70
Middlesex, , United Kingdom
Site 191
Newcastle upon Tyne, , United Kingdom
Site 43
Sutton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Machiels JP, Fayette J, Haddad R, Adkins D, Gillison M, Harrington KJ, Kim SB, Le Tourneau C, Psyrri A, Rosenberg A, Siu LL, Tahara M, William WN Jr, Ford J, Jauhari S, Pyle R, Shen YM, Yao D, Zohren F, Vokes E. LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC. Future Oncol. 2025 Jul;21(16):2007-2016. doi: 10.1080/14796694.2025.2511470. Epub 2025 Jun 13.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-510322-32
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
MCLA-158-CL02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.